Kiniksa [KNSA] vs Lantheus Holdings [LNTH] Detailed Stock Comparison

Kiniksa Pharmaceuticals, Ltd.

NASDAQ
Loading...

Lantheus Holdings Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Kiniksa Pharmaceuticals, Ltd. wins in 3 metrics, Lantheus Holdings Inc. wins in 17 metrics, with 0 ties. Lantheus Holdings Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Kiniksa Pharmaceuticals, Ltd. Lantheus Holdings Inc. Better
P/E Ratio (TTM) 57.39 24.30 Lantheus Holdings Inc.
Price-to-Book Ratio 5.78 4.91 Lantheus Holdings Inc.
Debt-to-Equity Ratio 1.67 57.19 Kiniksa Pharmaceuticals, Ltd.
PEG Ratio -0.22 -0.04 Lantheus Holdings Inc.
EV/EBITDA 36.68 14.70 Lantheus Holdings Inc.
Profit Margin (TTM) 8.71% 15.15% Lantheus Holdings Inc.
Operating Margin (TTM) 9.78% 19.07% Lantheus Holdings Inc.
EBITDA Margin (TTM) 9.78% 19.07% Lantheus Holdings Inc.
Return on Equity 11.73% 21.45% Lantheus Holdings Inc.
Return on Assets (TTM) 7.18% 9.28% Lantheus Holdings Inc.
Free Cash Flow (TTM) $136.42M $348.64M Lantheus Holdings Inc.
1-Year Return 76.83% 31.42% Kiniksa Pharmaceuticals, Ltd.
Price-to-Sales Ratio (TTM) 4.86 3.50 Lantheus Holdings Inc.
Enterprise Value $2.89B $5.62B Lantheus Holdings Inc.
EV/Revenue Ratio 4.27 3.65 Lantheus Holdings Inc.
Gross Profit Margin (TTM) 54.99% 59.21% Lantheus Holdings Inc.
Revenue per Share (TTM) $9 $23 Lantheus Holdings Inc.
Earnings per Share (Diluted) $0.75 $3.41 Lantheus Holdings Inc.
Beta (Stock Volatility) 0.06 -0.13 Lantheus Holdings Inc.
Short % of Float 9.62% 10.95% Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd. vs Lantheus Holdings Inc. Stock Performance Analysis

Loading Price Chart...

KNSA
LNTH

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Kiniksa Pharmaceuticals, Ltd.2.02%-11.22%-18.55%2.02%17.12%11.71%
Lantheus Holdings Inc.4.09%-3.76%9.71%26.21%64.47%43.15%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Kiniksa Pharmaceuticals, Ltd.76.83%231.14%262.67%149.25%149.25%149.25%
Lantheus Holdings Inc.31.42%11.99%303.82%4,393.21%1,444.32%1,444.32%

Performance & Financial Health Analysis: Kiniksa Pharmaceuticals, Ltd. vs Lantheus Holdings Inc.

MetricKNSALNTH
Market Information
Market Cap i$3.29B$5.39B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i755,851641,334
90 Day Avg. Volume i660,037839,568
Last Close$47.87$100.24
52 Week Range$26.27 - $59.87$47.25 - $103.89
% from 52W High-20.04%-3.51%
All-Time High$59.87 (May 12, 2026)$126.89 (Jul 15, 2024)
% from All-Time High-20.04%-21.00%
Growth Metrics
Quarterly Revenue Growth0.65%0.04%
Quarterly Earnings Growth0.65%0.04%
Financial Health
Profit Margin (TTM) i0.09%0.15%
Operating Margin (TTM) i0.10%0.19%
Return on Equity (TTM) i0.12%0.21%
Debt to Equity (MRQ) i1.6757.19
Cash & Liquidity
Book Value per Share (MRQ)$7.44$16.87
Cash per Share (MRQ)$5.41$5.56
Operating Cash Flow (TTM) i$137.98M$390.14M
Levered Free Cash Flow (TTM) i$97.89M$265.57M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Kiniksa Pharmaceuticals, Ltd. vs Lantheus Holdings Inc.

MetricKNSA (Apr 24, 2026)LNTH (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i57.3924.30
Forward P/E i29.1513.17
PEG Ratio i-0.22-0.04
Price to Sales (TTM) i4.863.50
Price to Book (MRQ) i5.784.91
Market Capitalization
Market Capitalization i$3.29B$5.39B
Enterprise Value i$2.89B$5.62B
Enterprise Value Metrics
Enterprise to Revenue i4.273.65
Enterprise to EBITDA i36.6814.70
Risk & Other Metrics
Beta i0.06-0.13
Book Value per Share (MRQ) i$7.44$16.87

Financial Statements Comparison: Kiniksa Pharmaceuticals, Ltd. vs Lantheus Holdings Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricKNSA (2025)LNTH (2025)
Revenue/Sales i677.56M1.54B
Cost of Goods Sold i307.22M599.66M
COGS % of Revenue i45.3%38.9%
Gross Profit i370.35M941.95M
Gross Margin i54.7%61.1%
Research & Development i96.85M177.31M
Operating Income (EBIT) i77.22M315.56M
Operating Margin i11.4%20.5%
EBITDA i78.78M409.00M
EBITDA Margin i11.6%26.5%
Pre-Tax Income i88.87M313.79M
Pre-Tax Income % of Revenue i13.1%20.4%
Income Tax i29.86M80.23M
Income Tax % of Revenue i4.4%5.2%
Net Income (Profit) i59.01M233.56M
Profit Margin i8.7%15.2%

Balance Sheet & Liquidity Metrics

MetricKNSA (2025)LNTH (2025)
Cash & Equivalents i165.60M359.12M
Total Current Assets i527.18M899.96M
Total Current Assets % of Revenue i77.8%58.4%
Total Current Liabilities i139.18M333.42M
Total Current Liabilities % of Revenue i20.5%21.6%
Long-Term Debt i6.51M618.69M
Long-Term Debt % of Revenue i1.0%40.1%
Total Shareholders Equity i567.61M1.09B
Retained Earnings i-462.14M679.50M
Retained Earnings % of Revenue i-68.2%44.1%
Property, Plant & Equipment i13.81M30.98M

Cash Flow Statement Comparison

MetricKNSA (2025)LNTH (2025)
Operating Cash Flow i124.01M398.13M
Operating Cash Flow % of Revenue i18.3%25.8%
Capital Expenditures i-1.57MN/A
Free Cash Flow i136.42M348.64M
FCF Margin i20.1%22.6%
Debt Repayment iN/A-1.11M
Common Stock Repurchase i-7.73M-300.02M

Short Interest & Institutional Ownership Analysis

MetricKNSALNTH
Shares Short i4.09M5.36M
Short Ratio i6.094.60
Short % of Float i9.62%10.95%
Shares Outstanding i76.29M64.59M
Float Shares i39.90M58.18M
% Held by Insiders i3.58%2.04%
% Held by Institutions i103.89%109.34%
% Held by Public i-7.47%-11.38%

Dividend Analysis & Yield Comparison: Kiniksa Pharmaceuticals, Ltd. vs Lantheus Holdings Inc.

MetricKNSALNTH
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A